cbdMD Q4 2023 Earnings Report

cbdMD EPS Results

• Actual EPS: -$9.06
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

cbdMD Revenue Results

• Actual Revenue: $4.87 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

cbdMD Announcement Details

• Quarter: Q4 2023
• Date: 12/22/2023
• Time: N/A

cbdMD (NYSEAMERICAN:YCBD) produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, and sleep, focus, and calming aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand. It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is headquartered in Charlotte, North Carolina.